🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

265 results for “LG” Clear

  1. DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  2. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  3. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. Epoetin alga (Epogen)/vadadustat

    Akebia Europe Limited

    Anemia Associated With Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  5. Erenumab

    United Therapeutics Europe Ltd

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  6. FILGRASTIM, CYCLOPHOSPHAMIDE, DOXORUBICIN, DEXRAZOXANE HYDROCHLORIDE

    Ningbo Cancer Hospital

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

  7. FMX-101, 4% minocycline foam

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    2 trials

  8. FMX101

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  9. FMX101

    Cutia Therapeutics (Shanghai) Co., Ltd

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  10. FUROSEMIDE , DULOXETINE

    Ningbo Cancer Hospital

    ER positive HER2 negative breast cancer stages I-II

    phase 3 small molecule active

    1 trial

  11. Filgotinib

    Alfasigma S.p.A.

    Axial Spondyloarthritis

    phase 3 small molecule active

    1 trial

  12. Filgotinib

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  13. Filgotinib

    Lakefront Biotherapeutics NV

    Ankylosing Spondylitis

    phase 3 small molecule terminated

    3 trials

  14. Filgotinib

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 3 small molecule completed

    2 trials

  15. Filgotinib

    Lakefront Biotherapeutics NV

    Psoriatic Arthritis

    phase 3 small molecule terminated

    4 trials

  16. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  17. GSK2585823(CLDM 1%-BPO 3% gel)

    GlaxoSmithKline

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  18. Genotype-guided dosingTaiwan algorithm for warfarin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 3 gene therapy completed

    1 trial

  19. HD201

    Prestige Biopharma Belgium

    HER2 Positive Breast Cancer

    phase 3 small molecule completed

    1 trial

  20. Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , BORTEZOMIB, DARZALEX 1800 mg solution for injection, Dexamethason-ratiopharm® 4 mg Tabletten, Iberdomide, Iberdomide

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  21. Imnovid 1 mg hard capsules, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, Imnovid 4 mg hard capsules, Dexamethason CF 20 mg/ml, injectievloeistof, CC-92480, Dexamethason 4 mg JENAPHARM®, Imnovid 2 mg hard capsules, DEXAMETHASONE, Dexamethason 4 mg GALEN®, CC-92480, Imnovid 3 mg hard capsules, CC-92480, CC-92480, VELCADE 1 mg powder for solution for injection

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  22. LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CYTARABINE, METHOTREXATE, CYTARABINE, PREDNISONE, METHOTREXATE, Melphalan 50 mg powder and solvent for solution for injection/infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, Idarubicina Sandoz 1 mg/ml concentrato per soluzione per infusione, METHOTREXATE, PREDNISONE, FILGRASTIM, Glivec 100 mg hard capsules, CYTARABINE, PURINETHOL 50 mg compresse, Dexamethasone Phosphate 4 mg/ml Solution for Injection, Keppra 250 mg film-coated tablets, ME

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    phase 3 small molecule active

    1 trial

  23. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  24. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources